{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJLjuZcJDA","lastupdate":"2024-08-26T00:00:00.000Z","update_date":"2024-08-26T00:00:00.000Z","lastModified":"Oct 5, 2025","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"novasight","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$xmyFeivd3V6f8mvAA8VWJ3ceJHjcgbG1u99SqtWjtpwRNvXVbRJcMc","name":"NovaSight","oneliner":"Eye-Tracking Based Solutions for Pediatric Vision Care","registrar":"514734516","website":"https://nova-sight.com","careerspage":"","founded_month":2,"founded_year":2016,"formernames":[],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/channel/UCH-mzhGrUbVVwfzNwhQuA-g","facebook":"https://www.facebook.com/profile.php?id=61564025591075","linkedin":"https://www.linkedin.com/company/11101854","instagram":"https://www.instagram.com/nova_sight2016/"},"social":["https://www.facebook.com/profile.php?id=61564025591075","https://www.linkedin.com/company/11101854","https://www.youtube.com/channel/UCH-mzhGrUbVVwfzNwhQuA-g","https://www.instagram.com/nova_sight2016/"],"flattenedsociallinks":"https://www.facebook.com/profile.php?id=61564025591075|https://www.linkedin.com/company/11101854|https://www.youtube.com/channel/UCH-mzhGrUbVVwfzNwhQuA-g|https://www.instagram.com/nova_sight2016/","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":14,"patent":1,"raised":30970000,"stage":"A","public_stage":"A","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Novasight","Nova-Sight","Nova Sight"],"about":"NovaSight is medical device company with a mission to prevent vision impairments among pediatric patients using eye tracking based technology in novel diagnostic, therapeutic and preventive solutions, especially designed for the unique needs of children. NovaSight focuses on three major verticals: vision treatment, vision diagnostics and prevention and monitoring of visual health conditions. Available in the US and Italy, the CureSight™ is an FDA cleared and CE marked amblyopia treatment system, designed to replace the traditional eye patching. The treatment is carried out while the patient watches his favorite streamed content from the comfort of home. By tracking the gaze position of the dominant eye in real-time, the CureSight system blurs its center of vision, while keeping the rest of the image sharp - and providing the amblyopic eye with a normal, high contrast, image. This stimulates the brain to complete the blurred image from the amblyopic eye, improving its acuity and developing stereoacuity as the eyes learn to work together. In addition, the CureSight system is connected to a dedicated cloud platform which allows the physician to monitor treatment progress and compliance remotely. The EyeSwiftPRO tests are grouped into automated ‘protocols’ such as amblyopia monitoring, binocular vision, etc. with each protocol running the unitary tests that are of clinical relevance to the protocol. At the end of each protocol, a clear report which is easily understood by the operator and the patient is created. NovaSight is also in the process of developing TrackSight™, a software as a service (SaaS) solution for myopia prevention and visual health monitoring. TrackSight is designed for use by children on laptops and tablets for both educational and leisure purposes as well as adults at the workplace for objective eye fatigue and dry eye monitoring.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97236422868","country":null,"address":{"israeli":[{"id":"2tUsxaotHKvRY1JnrQqQZVKbBwQFdq244OY5vvhFMzZVgTpLFYNdeF","city":"Lod","type":null,"address":"Lod, Israel","placeid":"ChIJoQbRWlzKAhURGoHKB15E7qw","notactive":null,"openeddate":null,"registrarid":null,"firstrdcenter":null,"registrarname":null}],"officesabroad":[{"id":"QlZiDjW0A20pBtoMM7INtmaXE34WTS1FQbj4klLPh8OeHd8prqx7wN","city":null,"address":"Virginia, USA","country":"United States","placeid":"ChIJzbK8vXDWTIgRlaZGt0lBTsA"}]},"headquarter_address":null,"district":"Center District","news":[{"id":"ncBzBtC1OP8NZRChVbRMCDcs4Z2N6SKW61IOpUCkjS1W9ZlU7x2X39","date":"Nov 19, 2024","link":"https://www.ophthalmologytimes.com/view/binocular-amblyopia-home-treatment-the-next-step-after-patching","source":"www.ophthalmologytimes.com","visible":1,"analysis":{"tags":"amblyopia treatment","company":"NovaSight","layoffs":null,"summary":"The article discusses a study comparing the efficacy of a binocular, eye-tracking-based home treatment for amblyopia, CureSight, developed by NovaSight, against traditional patching. The study, published in the American Journal of Ophthalmology, involved 149 children aged 4 to 9 years and demonstrated that CureSight is at least as effective as patching in improving visual acuity. CureSight encourages binocular vision, reducing interocular suppression, and showed higher adherence rates compared to patching. The study found that both treatments improved visual acuity, with CureSights improvement margin within the acceptable range of noninferiority to patching. The findings suggest that CureSight is a safe and engaging alternative to patching, with significant benefits for patients.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["amblyopia","binocular treatment","visual acuity","adherence rates","clinical trial"],"date_of_event":"2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"riKiIfV3FijMBXfXiUK10hCzuIAGsnXaMuaofvFrbiyUfExWBD3QOP","news_summary":"Binocular amblyopia home treatment: The next step after patching","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"1r1rYUSjFFlp9Ugety42AGM1PwVTPh1UOaQXUWNS7nexR9MoMjMWSb","date":"Sep 12, 2024","link":"https://www.healio.com/news/optometry/20240912/curesight-demonstrates-greater-visual-acuity-gains-vs-patching-in-patients-with-amblyopia","source":"www.healio.com","visible":1,"analysis":{"tags":"innovation","company":"NovaSight","layoffs":null,"summary":"NovaSights CureSight digital eye-tracking system has demonstrated superiority over traditional patching methods in treating amblyopia, according to a study published in the American Journal of Ophthalmology. The study involved 149 children aged 4 to under 9 years, comparing the CureSight system with patching over a 16-week period. Results showed a significant improvement in visual acuity and treatment adherence in the CureSight group. The mean improvement in visual acuity was 0.28 logMAR for CureSight users compared to 0.23 logMAR for those using patches. Adherence to the CureSight regimen was also higher at 94% compared to 83.9% for patching. This breakthrough highlights NovaSights innovative approach to amblyopia treatment.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["CureSight","amblyopia","visual acuity","treatment","adherence"],"date_of_event":"September 4, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"z7U8m9XXRByp8yPcNM2w5ziPJctO5iuub7SVDp75xU86fMrgu7fbyO","news_summary":"CureSight demonstrates greater visual acuity gains vs. patching in patients with amblyopia","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"YbivX5qQ5Kqqg8rNLvEYVOhomRpRjND64AZM6CWVXsPG91ABOh5xEQ","date":"Mar 30, 2024","link":"https://www.calcalist.co.il/calcalistech/article/hyodfru1r?_atscid=7_134353_204082920_2559099_0_Txtetaxjxdshwhus8sp","source":"www.calcalist.co.il","visible":1,"analysis":{"tags":"Investment, Expansion","company":"נובה-סייט (Nova-Sight)","layoffs":"Not mentioned","summary":"Nova-Sight, a company developing medical equipment for eyes, has raised $5 million in a funding round led by Infinity, an Israeli-Chinese venture capital fund. The total funding round is expected to reach $10 million. The funds will be used to expand the companys global marketing and R&D activities. Nova-Sights device, CureSight, is designed to treat lazy eye in children and has shown significant improvement in vision clarity in clinical trials. The company, based in Airport City, employs 21 people.","partners":"Not mentioned","customers":"Not mentioned","investors":"אינפיניטי (Infinity)","confidence":9,"key_topics":["Investment","Medical Device","Eye Treatment","Global Marketing","Expansion"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$10 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OaY0b95dW2Z1Ca32VLoPQla5O6OosfYp8N1Gi6OQrwxNWvZvpcHP2h","news_summary":"בהובלת קרן ההון סיכון הישראלית-סינית אינפיניטי: נובה-סייט גייסה 5 מיליון דולר | כלכליסט","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"AR7jeQpN0K4ifjR35I69gy6XWTez51WkAME672rRdDt6oAcvzVwXpr","date":"Mar 14, 2024","link":"https://glance.eyesoneyecare.com/stories/2024-03-14/novasight-reports-long-term-vision-gains-in-curesight-study/","source":"glance.eyesoneyecare.com","visible":1,"analysis":{"tags":"Medical Equipment, Vision Care, AI, Eye-tracking","company":"NovaSight","layoffs":"N/A","summary":"NovaSight, a medical equipment manufacturer specializing in vision care solutions, has released 1-year follow-up outcomes for its CureSight treatment for amblyopia. The treatment, which uses AI and eye-tracking technologies, is designed to replace traditional eye patching methods. The study found that patients using CureSight showed significant improvement in visual acuity and stereoacuity compared to those using eye patches. The CureSight system was also found to significantly improve vision in amblyopic pediatric patients at least 1-year post-treatment.","partners":"N/A","customers":"Pediatric Patients","investors":"N/A","confidence":9,"key_topics":"CureSight, Amblyopia Treatment, Pediatric Vision Care, Clinical Trial, Treatment Outcomes","date_of_event":"2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers","acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YUe2YurUiodw5j7gp4icXYSg6FQCVoXDSoleTftPE2xtolc2pqGlRC","news_summary":"NovaSight reports long-term vision gains in CureSight study","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a8tEGi2RVIxXwIsaP13gKp1bpjk0nJw4hC5fj2AH58oFETvj8JYpCE","date":"Mar 13, 2024","link":"https://www.ophthalmologytimes.com/view/novasight-publishes-curesight-s-pivotal-study-of-1-year-follow-up-outcomes","source":"www.ophthalmologytimes.com","visible":1,"analysis":{"tags":"Healthcare, Technology","company":"NovaSight","layoffs":"Not mentioned","summary":"NovaSights CureSight, a digital at-home treatment for amblyopia (lazy eye), has demonstrated long-term vision gains in a study published in the American Journal of Ophthalmology. The study found that children showed significant improvement in visual acuity and stereoacuity following short-term binocular treatment with CureSight, and these gains were maintained for at least one year. Following FDA clearance in October 2022, NovaSight launched the CureSight Referral Program in the US in early 2023, which has been adopted by over 250 eye care providers and generated more than 650 patient referrals. NovaSight is planning a full commercial rollout in the US, Europe, and China in 2024.","partners":"Sheba Medical Center, Berkely University, Duke University, Cleveland Clinic, Thomas Eye Group, Seattle Children’s Hospital","customers":"Over 250 eye care providers","investors":"healthcare-focused venture capital firm","confidence":9,"key_topics":["CureSight","Amblyopia treatment","Clinical trial","Investment","Expansion"],"date_of_event":"March 13, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"f0dRq1rGwBhUuoQuQNRml1FzA5lfQhVJIA3NjCJJdbHqSQITYrTj3I","news_summary":"NovaSight publishes CureSight's pivotal study of 1-year follow-up outcomes","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"GQ9XkbW0cqV7gJrLdc6s4tWOD8zFSNoInIIo3JB9iMkrDGGmtv2RfK","date":"Jun 26, 2023","link":"https://nocamels.com/2023/06/children-watch-tv-to-cure-their-lazy-eye/","source":"nocamels.com","visible":1,"analysis":{"tags":"Healthcare, Technology","company":"NovaSight","layoffs":"N/A","summary":"NovaSight, an Israeli startup, has developed a new treatment for lazy eye (amblyopia) that allows children to treat their condition at home. The treatment, called CureSight, uses a specially developed tablet device and 3D-vision glasses to track the gaze of both eyes in real time using an AI sensor. The child watches any streamed video content of their choice through red-blue treatment glasses, which stimulate the brain to use the information of the lazy eye to process the fine details. The treatment has been found to be more effective than traditional patch treatment, with 79% of patients experiencing better vision correction after four months of use.","partners":"YouTube, Netflix, other streaming services","customers":"Children with lazy eye","investors":"N/A","confidence":9,"key_topics":["Lazy Eye Treatment","Eye Tracking","Data Analytics","Pediatric Vision Care","CureSight"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3JURd8fJAD7X5ORnJJLy3rR8ivyTsphLDxe4yYuXRSHZe16SSTTe1g","news_summary":"Israeli 3D Glasses To Combat Lazy Eye","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"wHHc14cEXOA3LBl5Zgeei5kNqwuQ7MSfdJo0yL9dxOvwOZONqWZWyL","date":"May 3, 2023","link":"https://www.accesswire.com/752936/NovaSight-CureSight-TM-Wins-2023-MedTech-Breakthrough-Award","source":"www.accesswire.com","visible":1,"analysis":{"tags":"Award, Innovation","company":"NovaSight","layoffs":"","summary":"NovaSights CureSight binocular digital treatment system for amblyopia (lazy eye) has been named Best New Technology Solution for Ophthalmology in the 7th annual MedTech Breakthrough Awards program. CureSight is an FDA-cleared and CE marked eye-tracking based amblyopia treatment system, designed to replace traditional eye patching. The treatment is carried out while the patient watches his favorite streamed content from home. The CureSight system blurs the center of vision of the dominant eye, while providing the amblyopic eye with a normal, high contrast image. This stimulates the brain to complete the blurred image from the amblyopic eye, improving its acuity and developing stereoacuity as the eyes learn to work together.","partners":"MedTech Breakthrough","customers":"Pediatric patients","investors":"","confidence":9,"key_topics":["Amblyopia treatment","MedTech Breakthrough Awards","Eye-tracking technology","Pediatric vision care","Digital vision care solutions"],"date_of_event":"May 4, 2023","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":["Customers"],"acquisition_amount":"","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"S87pnY6Ons8quSxNtDXuihjR0ginJAMTWjHhsTYOqf3e1EahrlNgAO","news_summary":"NovaSight CureSight (TM) Wins 2023 MedTech Breakthrough Award","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eZYPqrZs4hftX6sMC6ZSAaa8mUEDUOuLsxOng2X2dHMNkfVt5mwoEk","date":"Mar 29, 2023","link":"https://www.eyeworld.org/2023/insights-on-amblyopia-therapies/","source":"www.eyeworld.org","visible":1,"analysis":{"tags":"Digital Therapies, FDA Approval","company":"NovaSight, Luminopia","layoffs":"Not mentioned","summary":"Tech-based options for the treatment of amblyopia, such as CureSight by NovaSight and Luminopia, have received FDA approval and are now available on the market. These therapies allow for binocular treatment rather than monocular and have several studies published in peer review supporting their therapeutic benefits. However, patient compliance can pose a problem due to factors such as limited viewing options, the need for hardware and internet, and cost. Despite these challenges, these innovative therapies are applauded for improving the patient experience and compliance.","partners":"Not mentioned","customers":"Patients requiring amblyopia treatment","investors":"Not mentioned","confidence":9,"key_topics":"Amblyopia Treatment, Tech-Based Options, Patient Compliance, Cost-Effectiveness, FDA Approval","date_of_event":"March 2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Customers, Partners","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"fQ5jWHayebsMnTLetsCpbdfB23sk6hYwRpl8TTtV0gG8MMbdG9CyUX","news_summary":"Insights on amblyopia therapies - EyeWorld","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Mj1nDSqxbJrDAXMtlErplHbmO4vdenNOGi322uh77Dlf4nJX8YDjJn","date":"Dec 15, 2022","link":"https://eyewire.news/news/novasight-introduces-curesight-to-the-us-and-names-a-new-vp-of-sales-marketing?c4src=article:infinite-scroll","source":"eyewire.news","visible":1,"analysis":{"tags":"Product Launch, Management Changes","company":"NovaSight","layoffs":"N/A","summary":"NovaSight has announced the US release of its CureSight digital therapy for amblyopia. The device received FDA clearance based on a study that found it to be as effective as eye patching, the current standard of care. The therapy is carried out at home while the child watches streamed content on a user-friendly device, with treatment reports shared via a web portal. NovaSight also announced the appointment of Drew Hopper as Vice President of Sales and Marketing North America. The company aims to reach coverage from the top five US insurance payers in 2023.","partners":"N/A","customers":"Amblyopic patients","investors":"N/A","confidence":9,"key_topics":["CureSight Launch","FDA Clearance","Amblyopia Treatment","Drew Hopper Appointment","Insurance Coverage"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MpX6PK9bsBcysUZPFv9HON1ZTddHCeBt21MlGkCPbtaBnecoSbhizZ","news_summary":"NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketing - Eyewire+","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ZWtqNxJKQrPMMxb3qospVYgnZ8JFHrnKQVtA665ndRR7YicIYXayaY","date":"Oct 6, 2022","link":"https://www.visionmonday.com/eyecare/article/novasight-announces-fda-510k-clearance-of-curesight-digital-therapy-for-amblyopia/","source":"www.visionmonday.com","visible":1,"analysis":{"tags":"FDA Approval, Investment","company":"NovaSight","layoffs":"Not specified","summary":"NovaSight, a pediatric-focused eyecare company, has received clearance from the U.S. Food and Drug Administration (FDA) for CureSight, a digital therapy device for amblyopia. The device uses eye-tracking technology to improve visual and stereo acuity by training the visual system to use both eyes simultaneously. The FDA clearance was based on a study conducted in six medical centers in Israel. NovaSight recently raised $7 million in a SAFE (Simple Agreement for Future Equity) round, bringing the total amount raised by the company to $26 million. The funds will be used for the targeted commercialization of CureSight in the U.S.","partners":"Not specified","customers":"Not specified","investors":"Not specified","confidence":9,"key_topics":["FDA Clearance","CureSight","Amblyopia Treatment","Digital Therapy Device","Investment"],"date_of_event":"Not specified","valuation_amount":"Not specified","impact_on_company":"growth-positive","investment_amount":"$7 million","structured_issues":["Investment"],"acquisition_amount":"Not specified","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RNRokvcVzYiXPlKCsjPB1Ykfq2teoZkAmrgX3lhfFSx7n7cfnqLdal","news_summary":"NovaSight Announces FDA 510(K) Clearance of CureSight Digital Therapy for Amblyopia","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"083beaee-da84-4190-8fbd-b6f76f3c050b","date":"Mar 10, 2022","link":"https://www.globenewswire.com/news-release/2022/03/10/2400908/0/en/NovaSight-Announces-Successful-Results-of-Pivotal-Amblyopia-Treatment-Trial.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Healthcare, Technology","company":"NovaSight","layoffs":"Not mentioned","summary":"NovaSight, a pediatric-focused eyecare company, has announced positive data from its trial of CureSight, a digital treatment device for amblyopia, also known as lazy eye. The study demonstrated that the device was non-inferior to traditional eye patching treatment. The company also reported high patient satisfaction and adherence to the CureSight treatment. NovaSight has initiated a Series B financing round in addition to the $20 million it has already raised. The company is also preparing to submit its application for FDA clearance of the device.","partners":"Sheba Medical Center","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Eye Care","Clinical Trial","Investment","FDA Approval","Digital Treatment"],"date_of_event":"March 10, 2022","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$20 million","structured_issues":["Customers","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zCXlTBxB2ti5KKrncSIcbb0orMtOzx3YevVPoufjFwuzTikMCkJMMu","news_summary":"NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0d684756-a9ce-4604-8af9-cecd100707b3","date":"Jul 9, 2021","link":"https://www.visionmonday.com/eyecare/eye-health/article/novasight-is-assigned-three-unique-cpt-codes-by-ama-for-curesight-amblyopia-treatment/","source":"www.visionmonday.com","visible":1,"analysis":{"tags":"Healthcare, Pediatrics, Eyecare","company":"NovaSight","layoffs":"Not mentioned","summary":"NovaSight, a pediatric-focused eyecare company, has reached key milestones in the development of its CureSight digital treatment device for amblyopia, or lazy eye. The American Medical Association (AMA) has assigned three unique billing codes to the companys technology, marking the first time the AMA has awarded codes to an eye-tracking amblyopia treatment. These codes will allow physicians and patients to potentially be reimbursed for the use of CureSight. NovaSight is also sponsoring a clinical trial that will generate data about CureSight for inclusion in an early 2022 FDA clearance submission. The company is seeking additional partners for a series B funding effort anticipated to total $15 million.","partners":"EssilorLuxottica","customers":"Physicians and patients","investors":"Not mentioned","confidence":9,"key_topics":["CureSight","Amblyopia treatment","Clinical trial","Reimbursement structure","Health insurance"],"date_of_event":"Friday, July 9, 2021","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$15 million (anticipated)","structured_issues":["Customers","Partners","Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SZABSj0demjaX6GNuAkViRBXQAaISVtS9V39iuP14RRypy1YffDTTV","news_summary":"NovaSight Is Assigned Three Unique CPT Codes by AMA for CureSight Amblyopia Treatment","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5ac143ad-7230-4634-a256-7e4740f0792f","date":"Jul 9, 2021","link":"https://eyewire.news/articles/novasight-announces-establishment-of-three-unique-cpt-codes-for-the-curesight-digital-treatment-for-lazy-eye/","source":"eyewire.news","visible":1,"analysis":{"tags":"Healthcare, Technology","company":"NovaSight","layoffs":"Not mentioned","summary":"NovaSight has announced significant progress towards the launch of its CureSight digital treatment device for amblyopia, or lazy eye. The American Medical Association (AMA) has assigned three unique billing codes to the companys technology, marking the first time the AMA has awarded codes to an eye-tracking amblyopia treatment. This will allow physicians and patients to potentially be reimbursed for using CureSight. NovaSight is also sponsoring a clinical trial to generate data about CureSight for inclusion in a 2022 FDA clearance submission. The company is seeking additional partners for a series B funding effort anticipated to total $15 million.","partners":"EssilorLuxottica","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["CureSight","Amblyopia Treatment","Clinical Trial","Health Insurance Reimbursement","Investment"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$15 million (anticipated for series B funding)","structured_issues":["Customers","Partners","Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"jKSEwrAwxxOrPbDB9rCPh3VYckXpjgpW7bBrG9Lb8tVuJt82InjQBt","news_summary":"NovaSight Announces Establishment of Three Unique CPT Codes for the CureSight Digital Treatment for Lazy Eye - Eyewire+","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0a7a92a2-3b61-44f4-8056-3f5d28b5627f","date":"Jul 3, 2021","link":"https://www.healio.com/news/ophthalmology/20210702/video-curesight-platform-offers-amblyopia-therapy","source":"www.healio.com","visible":1,"analysis":{"tags":"Product Launch","company":"NovaSight","layoffs":"N/A","summary":"Ran Yam, CEO of NovaSight, discusses two upcoming product lines, CureSight and ActiveSight glasses. The company is planning the next steps for these products.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["CureSight","ActiveSight glasses","Product lines"],"date_of_event":"July 03, 2021","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers","acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tgDmTY6R1byZwxnBXNNARAEEe4tXkFooyO7whoxzYzjJsuF2e0M350","news_summary":"VIDEO: CureSight platform offers amblyopia therapy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ad4d0d72-fe0a-446c-984d-bac671587365","date":"Mar 16, 2021","link":"https://www.mobihealthnews.com/news/novasight-eyes-fda-clearance-upcoming-clinical-trial","source":"www.mobihealthnews.com","visible":1,"analysis":{"tags":"Clinical Trial, FDA Clearance","company":"NovaSight","layoffs":"Not mentioned","summary":"NovaSight, an Israeli digital eye treatment startup, has announced a clinical trial for its CureSight system, which aims to treat amblyopia, or lazy eye, without the need for patching. The device uses artificial intelligence eye-tracking technology to blur what the dominant eye sees, thereby strengthening the weaker eye. The device can be used at home and shares treatment reports with caregivers and parents through a mobile app. The new study is seeking 90 children with amblyopia between 4 and 9 years old and will take place in six different medical centers across Israel.","partners":"Sheba Medical Center","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["CureSight","Amblyopia Treatment","Clinical Trial","Digital Eye Treatment","FDA Clearance"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$8 million Series A","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JglcYTWfgDhkul9TFzepprutkLLdFUOm6EmtoxcR5HgBo9a2hKXBdp","news_summary":"NovaSight eyes FDA clearance with upcoming clinical trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c14a15c9-c91a-42e3-9d97-986caf402e18","date":"Jul 13, 2020","link":"https://en.globes.co.il/en/article-israeli-ai-eye-tracking-co-novasight-raises-8m-1001335659","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Investment, Research","company":"NovaSight","layoffs":"Not mentioned","summary":"Israeli vision care company NovaSight has raised $8 million in a Series A financing round led by Rimonci Capital, bringing the total amount raised by the company to $16 million. The funds will be used to advance research for the companys lazy eye treatment device and eye care products such as innovative eye tracking based active glasses for myopia control. The company is also focusing on developing telehealth solutions for remote diagnostics and home treatment.","partners":"Not mentioned","customers":"Not mentioned","investors":"Rimonci Capital","confidence":9,"key_topics":"Fundraising, Eye Care, Research, FDA Clearance, Telehealth","date_of_event":"July 13, 2020","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$8 million","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UsjTYlNrbBUirLZwJgib0aH3J9Y6G3Lo4ZRzUr7rs2nVYHF9DQW5Pn","news_summary":"Israeli AI eye tracking co NovaSight raises $8m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a8a9e249-ad9e-477a-8853-56944d0dfdf9","date":"Apr 20, 2020","link":"https://www.healio.com/ophthalmology/ophthalmic-business/news/online/%7B60c8ae79-4f04-41b0-9747-c6c4b75ae944%7D/novasight-launches-two-telehealth-technologies","source":"www.healio.com","visible":1,"analysis":{"tags":"Product Launch","company":"NovaSight","layoffs":"N/A","summary":"NovaSight has launched two products aimed at improving telehealth platforms through remote diagnostics and digital treatments. The EyeSwift is a vision assessment tool that monitors patient’s eye movements and provides evaluation of vision impairments. The CureSight specializes in lazy eye treatment, replacing traditional eye patching therapy with 3D image processing algorithms and patient progress monitoring. The systems treatment protocol is automatically adjusted through artificial intelligence.","partners":"N/A","customers":"Patients","investors":"N/A","confidence":9,"key_topics":"Telehealth, Remote Diagnostics, Digital Treatment, Vision Assessment, Lazy Eye Treatment","date_of_event":"April 08, 2020","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Om5QUQzzW2cqreAclUCOxkEoHSiRfy7zZ17qoBF5zhAJ5fpqJQQD5w","news_summary":"NovaSight launches two telehealth technologies","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e845f21c-33f1-410c-9fb9-3f7a478243e7","date":"Mar 30, 2020","link":"https://www.prnewswire.com/news-releases/novasight-answers-global-need-for-ophthalmology-telehealth-solutions-during-coronavirus-pandemic-301031657.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Product Launch, Telehealth","company":"NovaSight","layoffs":"Not mentioned","summary":"Israeli startup NovaSight has launched two eye-tracking based telehealth solutions for vision care, focusing on childrens vision. The CureSight system and the EyeSwift vision assessment system aim to provide improved remote diagnostics and digital treatments amidst the COVID-19 pandemic. The EyeSwift system, which provides 11 different vision exams, is currently marketed by NovaSights strategic partner, Essilor. NovaSights CureSight is an eye-tracking based system for lazy eye treatment, intended to replace traditional eye patching therapy. The company plans to conduct a large multicenter randomized trial during 2020.","partners":"Essilor","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Telehealth","Eye-tracking","Vision Care","Remote Diagnostics","Digital Treatment"],"date_of_event":"March 30, 2020","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Customers, Partners","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aBCLyAyTWgY7EU9UH9Xeix5rPf2EIwzwXmRYeYYpoTdgDtMbTBREFB","news_summary":"NovaSight Answers Global Need For Ophthalmology Telehealth Solutions During Coronavirus Pandemic","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ad1e0eeb-c3b8-4b08-87f7-e348547a4631","date":"Jan 21, 2020","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3779570,00.html","source":"www.calcalistech.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"cU0oZUOqZREin6fVKs0BygJpspdonog5J14JxTqD81F30RwZXf5t27","news_summary":"This Startup Cures Lazy Eye With Netflix and Disney","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"decad4b6-e1d5-4554-b89c-8e2bf0b83da9","date":"Jan 13, 2020","link":"https://techcrunch.com/2020/01/13/kids-with-lazy-eye-can-be-treated-just-by-letting-them-watch-tv-on-this-special-screen/","source":"techcrunch.com","visible":1,"analysis":{"tags":"Healthcare, Technology","company":"NovaSight","layoffs":"N/A","summary":"NovaSight has developed a new treatment for amblyopia, commonly known as lazy eye, that doesnt require the traditional method of wearing an eye patch. The companys CureSight technology uses a special display that selectively blurs content, forcing the affected eye to work harder and align itself properly. The treatment can be done at home and requires only an hour a day. NovaSight has already conducted limited clinical trials that showed significant improvement over a 12-week period. The company is planning further trials to determine if the treatment can completely cure the condition.","partners":"N/A","customers":"Patients with Amblyopia","investors":"N/A","confidence":9,"key_topics":"Amblyopia, CureSight, Eye Treatment, 3D Display Tech, Clinical Trials","date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers","acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FK5JRtxe9lcUa3VuE6vP15oAbNQfLQYNxPPpB4iN6FbgTrW7Ng4Ib0","news_summary":"Kids with lazy eye can be treated just by letting them watch TV on this special screen","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"16fa7596-5f1f-4ac3-b09e-ea62a4f69ab5","date":"Dec 17, 2019","link":"https://www.prnewswire.com/news-releases/novasight-leverages-netflix-and-disney-to-cure-vision-disorders-300976059.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"AI, Healthcare, Vision Care","company":"NovaSight","layoffs":"Not mentioned","summary":"NovaSight, a provider of digital healthcare platforms, is set to present its AI-driven eye tracking solutions for vision care at CES 2020. The companys CureSight solution aims to replace traditional eye patching for amblyopia treatment with AI and eye tracking technologies. The system uses eye tracking technology to blur the gaze position of the dominant eye, forcing the brain to use the amblyopic eye. NovaSight has also signed a global OEM distribution agreement with Essilor for its EyeSwift system, an automated, objective, and easy-to-use eye tracking based vision assessment system.","partners":"Essilor","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["AI-driven eye tracking","Vision Care","Amblyopia Treatment","CureSight","EyeSwift"],"date_of_event":"Dec. 17, 2019","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QZigZTnZdob0ud7uSkKwPdoW6Ceo49C4KzSY9cuC2ATSGZUx9oXrsX","news_summary":"NovaSight Leverages Netflix and Disney to Cure Vision Disorders","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ca21cf37-6b9c-49cb-9a0f-299972c748a9","date":"Aug 7, 2019","link":"https://www.israel21c.org/topic/novasight/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"Sustainability","company":"Keep It Magniv","layoffs":"N/A","summary":"The article introduces Keep It Magniv, a community focused on sustainability, environmentalism, and combating climate change. The platform aims to make a positive global impact and is inviting people to join and contribute to its cause. No specific details about partnerships, investments, or customers are mentioned.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":7,"key_topics":["Sustainability","Environmentalism","Climate Change","Global Impact","Community"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"Growth-Positive","investment_amount":"N/A","structured_issues":"Customers","acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"BgCyxwGvGPcCJBlZv8XhqFo5a6icmG3rHgnJldGfRZQQqOXYFrvgXc","news_summary":"NovaSight Archives - ISRAEL21c","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5424c935-6406-496c-9dd6-7d22d4a525d2","date":"Aug 13, 2018","link":"https://en.globes.co.il/en/article-novasight-wants-to-diagnose-vision-problems-1001249883","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Healthcare, Technology","company":"NovaSight","layoffs":"N/A","summary":"Israeli company NovaSight has developed a system that diagnoses and treats vision problems in children by monitoring eye movements. The system is particularly effective in diagnosing and treating lazy eye and convergence insufficiency. The company was founded by Dan Oz, who previously co-founded Sightline, a colonoscopy company that was sold to Stryker for $50 million. NovaSights product has been approved for marketing in Europe and is currently being tested on children. The company is also in talks with an international company to integrate its products into devices sold to ophthalmologists clinics.","partners":"International Company (unnamed)","customers":"Doctors, Optometrists","investors":"N/A","confidence":9,"key_topics":"Eye Health, Vision Correction, Technology, Market Expansion, Clinical Trials","date_of_event":"August 13, 2018","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Partners, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Partners, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2BI2ZfiP4gV4GKOYEmzIUwT7YfjkKJoq8R5g0JZAUX4g8ie7oIh5FD","news_summary":"Diagnosing vision problems from eye movement","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5594e001-ba62-44e8-81da-b80a6468ded1","date":"May 24, 2018","link":"https://www.israel21c.org/10-breakthrough-health-techs-emerging-from-israel/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"Healthcare, Biomed, Innovation","company":"CorNeat Vision, PixCell Medical, SpacePharma, NovaSight, Alpha Tau Medical, Neurosteer, Brainvivo, TempraMed, E-Motion Medical, BarimOte","layoffs":"N/A","summary":"The annual MIXiii-Biomed conference in Tel Aviv, Israel showcased 45 startups developing healthcare products in various fields. The event, sponsored by the Israel Innovation Authority (IIA), featured a competition for Biomed Startup of the Year. The winners were CorNeat Vision, which has developed an artificial cornea, and PixCell Medical, which is developing a bedside blood-count device. Other notable startups included SpacePharma, which is making experiments in space more accessible and affordable, and NovaSight, which has developed a technology based on eye-tracking to help children with vision disorders.","partners":"Israel Innovation Authority","customers":"Healthcare professionals, investors, engineers, scientists","investors":"Israel Innovation Authority","confidence":8,"key_topics":"Healthcare Innovation, Biomed Conference, Startup Competition, Medical Devices, Biotech","date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Partners","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"53RNUDBYFC3FOLUE4FIjdZt9eSpvoXhRAzV32DFPriEnh9S4wBrnpr","news_summary":"10 breakthrough health techs emerging from Israel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":24,"techcommunityinvolvement":null,"mediagallery":[{"id":"8FScaQnwoORa1PZmQMhNliMBy7QyL0hKSxQqFyyKZSunNN0JJbmy3H","timestamp":"2024-12-17 13:17:41.000000","resources_type":2,"resources_title":"EyeFlex - Vision Training System","resources_file_name":"dRm8ZkU8Yj0","alt":"EyeFlex - Vision Training System logo","imageurl":"https://img.youtube.com/vi/dRm8ZkU8Yj0/0.jpg","url":"http://youtu.be/dRm8ZkU8Yj0"},{"id":"ASg6UfWuRHyY1llhxmWBFGfpdnqvN1tkQkXXZ4RZQa0j7h3KSNs5op","timestamp":"2024-03-20 12:52:09.000000","resources_type":2,"resources_title":"NovaSight company video","resources_file_name":"THWmioDtaLc","alt":"NovaSight company video logo","imageurl":"https://img.youtube.com/vi/THWmioDtaLc/0.jpg","url":"http://youtu.be/THWmioDtaLc"},{"id":"KjVBX4D3qYBSvIvrRkOJDIanwA3vO8rjgS7BzH4CCsqvonlaJ4TzGB","timestamp":"2024-03-20 12:52:09.000000","resources_type":2,"resources_title":"CureSight video testimonial - Dr. John DeVaro","resources_file_name":"NLdsP2NDnhM","alt":"CureSight video testimonial - Dr. John DeVaro logo","imageurl":"https://img.youtube.com/vi/NLdsP2NDnhM/0.jpg","url":"http://youtu.be/NLdsP2NDnhM"},{"id":"vFw9kMwALvhWC2j2Qu6qUNUmVXRA7Wh91XHYqdWlcIyapq58TXjbuZ","timestamp":"2024-03-20 12:52:09.000000","resources_type":2,"resources_title":"CureSight patient testimonial - Ela Bertan","resources_file_name":"HBFmLk57_W0","alt":"CureSight patient testimonial - Ela Bertan logo","imageurl":"https://img.youtube.com/vi/HBFmLk57_W0/0.jpg","url":"http://youtu.be/HBFmLk57_W0"},{"id":"EZmBmuUct3KLwf3cdY94hlkM4DdSbFz9LY7rYt9XB5IPmghsc9nQPu","timestamp":"2023-09-20 11:47:55.000000","resources_type":1,"resources_title":"CureSight Technology (2)","resources_file_name":"$nK64kHBLGAThZCGc9aewXJkVyi0j0tcxY3Q6sExoTPFgFxj6szfl0V.png","alt":"CureSight Technology (2) logo","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$nK64kHBLGAThZCGc9aewXJkVyi0j0tcxY3Q6sExoTPFgFxj6szfl0V.png","url":"https://storage.googleapis.com/clean-finder-353810/$nK64kHBLGAThZCGc9aewXJkVyi0j0tcxY3Q6sExoTPFgFxj6szfl0V.png"},{"id":"LLezfVy6EjNL07fC8P4JnbgrGNYR7CZUklOQhP9ekhhi1Wi27J5MgT","timestamp":"2023-09-20 11:47:55.000000","resources_type":1,"resources_title":"","resources_file_name":"$pOkNVzpjSaDv2CjdPIyFbb4rBdQwVwhqYDsNX3Oj5kxqwbJX8rzJmA.png","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$pOkNVzpjSaDv2CjdPIyFbb4rBdQwVwhqYDsNX3Oj5kxqwbJX8rzJmA.png","url":"https://storage.googleapis.com/clean-finder-353810/$pOkNVzpjSaDv2CjdPIyFbb4rBdQwVwhqYDsNX3Oj5kxqwbJX8rzJmA.png"},{"id":"TJtgaAyGjTt8iXpkSrZirEFuh5MmIrQc7iD9yyVMh627QGm2G4EJHS","timestamp":"2023-09-20 11:47:55.000000","resources_type":1,"resources_title":"CureSight Technology","resources_file_name":"$JdJzcr6OS2Fkw2nvuvjdSppli4znHDXPv2xFv5laW62I7wpJOCyYeG.png","alt":"CureSight Technology logo","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$JdJzcr6OS2Fkw2nvuvjdSppli4znHDXPv2xFv5laW62I7wpJOCyYeG.png","url":"https://storage.googleapis.com/clean-finder-353810/$JdJzcr6OS2Fkw2nvuvjdSppli4znHDXPv2xFv5laW62I7wpJOCyYeG.png"},{"id":"mcx8i5tRup6mTm95SMJjvwH9pmf14y6I9BmhHAOWBIByYx2HWRuCh9","timestamp":"2023-09-20 11:40:24.000000","resources_type":1,"resources_title":"EyeSwift PRO Usability Video","resources_file_name":"$W6F2TsdLkZ4ZJ69L49gHwpgiziNrgta7FdWtHDwceM4qL6I1c0nQbb.png","alt":"EyeSwift PRO Usability Video logo","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$W6F2TsdLkZ4ZJ69L49gHwpgiziNrgta7FdWtHDwceM4qL6I1c0nQbb.png","url":"https://storage.googleapis.com/clean-finder-353810/$W6F2TsdLkZ4ZJ69L49gHwpgiziNrgta7FdWtHDwceM4qL6I1c0nQbb.png"},{"id":"7762c4f7-925e-4d07-8185-e02925b4dadd","timestamp":"2021-12-06 07:09:33.000000","resources_type":2,"resources_title":"CureSight - Eye Tracking Based Amblyopia Treatment","resources_file_name":"7rUku2wFtUA","alt":"CureSight - Eye Tracking Based Amblyopia Treatment logo","imageurl":"https://img.youtube.com/vi/7rUku2wFtUA/0.jpg","url":"http://youtu.be/7rUku2wFtUA"},{"id":"4deae31e-e48f-48c1-87f6-daaf0f956eba","timestamp":"2019-12-26 10:04:55.000000","resources_type":2,"resources_title":"NovaSight Channel 13 English subtitles","resources_file_name":"LAxRlbTWzw0","alt":"NovaSight Channel 13 English subtitles logo","imageurl":"https://img.youtube.com/vi/LAxRlbTWzw0/0.jpg","url":"http://youtu.be/LAxRlbTWzw0"},{"id":"f67db779-1c9e-4ec7-8ba4-1bff68456975","timestamp":"2019-12-26 10:04:27.000000","resources_type":2,"resources_title":"NovaSight Channel 13 - Short version English subtitles","resources_file_name":"rUVfv9mmzbY","alt":"NovaSight Channel 13 - Short version English subtitles logo","imageurl":"https://img.youtube.com/vi/rUVfv9mmzbY/0.jpg","url":"http://youtu.be/rUVfv9mmzbY"}],"tags":["patient-care","cloud","sensors","software-applications","optics","deep-learning","artificial-intelligence","wearable","healthcare","children","diagnostics","hospitals","ophthalmology","doctors","eye-diseases","medical-devices","healthcare-providers","computer-vision","digital-healthcare","early-detection","screening","data-analytics","non-invasive","big-data","real-time","parents","telemedicine","eye-tracking","optronics","digital-therapeutics","treatments","home-care","consumers","medical-technologies","training"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pv12fQLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8u-QLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B2C","B2B","B2C"],"productstage":"Released","products":["EyeSwift","CureSight","EyeFlex","TrackSight","EyeSwift pro"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":9,"lastfunding":"Undisclosed","totalrounds":6,"fundingstage":"A","totalfunding":"$30.97M","publicinvestors":9,"lastpublicfunding":0,"totalpublicrounds":6,"totalpublicfunding":30970000},"team":[{"name":"Ran Yam","email":"ran@nova-sight.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoOqM0ZALDA","bounced":false,"claimed":0,"founder":0,"urlname":"ran-yam","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgkvH_gwkM","position":"CEO","last_name":"Yam","claimtoken":"d506c44lDN21EUz0vQA8vS5Zc3V8B754fS4wULS1Drk1QikNUeB1nw","first_name":"Ran","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ran-yam-19baa235/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-08-26 14:58:25.000000","initials":"RY","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Danny Oz","email":"danny@nova-sight.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoJKEl58JDA","bounced":false,"claimed":0,"founder":1,"urlname":"danny-oz","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgkrPVkQoM","position":"Founder & CTO","last_name":"Oz","claimtoken":"0nVPafF3hDp5b7a1izeGOG8I4a8NUE3fUQ6wg8NZPDXLdXA4HcxICh","first_name":"Danny","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/danny-oz-0652ba6/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-09-20 11:49:59.000000","initials":"DO","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Oren Yehezkel","email":"oren.yehezkel@gmail.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4KzTi60LDA","bounced":false,"claimed":1,"founder":0,"urlname":"oren-yehezkel","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgnOrJjAkM","position":"CSO","last_name":"Yehezkel","claimtoken":"b8193086abe4194a715af4b5af738aa934877a13ffbb768095dc27b685574384","first_name":"Oren","picturekey":"$21SeZ8At4BnuUvbILgjpVbmMHiOrDRf8AOcXjU4K20RH5sqVXerqLZ","claimeddate":"2019-07-15","linkedinurl":"https://www.linkedin.com/in/oren-yehezkel-0615aa50/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2019-07-15 13:13:41.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$21SeZ8At4BnuUvbILgjpVbmMHiOrDRf8AOcXjU4K20RH5sqVXerqLZ","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Danny Atar","email":"atard@nova-sight.com","phone":"050-759-1611","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkNia59UIDA","bounced":false,"claimed":0,"founder":0,"urlname":"danny-atar","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQmJ6DzAgM","position":"VP Operation","last_name":"Atar","claimtoken":"OkFX9eybkVzu1FTdjkBg7SAYzv7zDhHQ18gMNee2eav4YAVXW0BAe7","first_name":"Danny","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/danny-atar-7594a9/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-09-20 11:50:03.000000","initials":"DA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Tal Samet","email":"tal@nova-sight.com","phone":"","gender":"Male","userid":"25AKfYh6UqReBtvrl3UQCCSQS5kMkq4JXuPZYMcLseAh29wudS0GpK","bounced":true,"claimed":null,"founder":0,"urlname":"tal-samet","visible":1,"memberid":"kgGRCvIg3pO0unY66RdtE0h52MGTO966wJUqdqk2jPyfgUNl7XxPMd","position":"VP R&D","last_name":"Samet","claimtoken":null,"first_name":"Tal","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"TS","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Liron  Rosenbaum","email":"liron@nova-sight.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkNjkttQJDA","bounced":true,"claimed":1,"founder":0,"urlname":"liron-rosenbaum","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQ6KDSgAoM","position":"VP Strategy","last_name":"Rosenbaum","claimtoken":"6c4291fac5313c4470ca0343de2a029d6597bc1018da53d3b18bebcb3fc9d645","first_name":"Liron ","picturekey":null,"claimeddate":"2021-12-06","linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2021-12-06 12:08:14.000000","initials":"LR","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwPi8kYoKDA","fullname":"Ayelet Beazley"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-05-08T00:00:00.000Z","crunchbaseid":"novasight-8b62","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Vered Waxman","creator_email":"vered.waxman@sncentral.org","createdate":"2017-11-21T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Ayelet Beazley","affiliatedOrganizations":null,"timeline":[{"id":"aBu2AwANuitKqwXAjOpwnbayn2Aby4ICBK1MoiQ8tM89eSnvNBS8Ua","date":"Jul 2025","amount":"Undisclosed","source":"Silent round - Eli Yered from Sanara Capital","eventtype":"FundingRoundEvent","investment":[{"name":"Sanara Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/sanara-capital","logokey":"$OtrwiBbgsSI76jjQf5e00ig2pAnDSClBhkfRBSLW92Zf7whDq9YrQr.jpeg","tagline":null,"urlname":"/investor_page/sanara-capital","isisraeli":1,"investorid":"5xOGxLkkR8sf5lZkhz50eFzCcebcLx4AdZMgruBnsbEkjIOO0mLnkG","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"xE02tp4C2uOvOvqwHHjGKQVmkXvEYzsa9liJYB5jYgUIh1ouVVXQa1","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$OtrwiBbgsSI76jjQf5e00ig2pAnDSClBhkfRBSLW92Zf7whDq9YrQr.jpeg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"bc7tbTIUaIKJHaAwT6WEqRBgPDfZJgx0vUePJZDj1R7uB9a6tNU0Kv","date":"Mar 2024","amount":"$5M","source":"https://www.calcalist.co.il/calcalistech/article/hyodfru1r?_atscid=7_134353_204082920_2559099_0_Txtetaxjxdshwhus8sp","eventtype":"FundingRoundEvent","investment":[{"name":"Infinity China","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/infinity-china","logokey":null,"tagline":"","urlname":"/investor_page/infinity-china","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCOzOinCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"cy7Mmti0Z25uAjOgbpg5iAfbvQGEfR6V9DI2YOz6DtrScm2TUjR9zF","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"JGhYTypY3TUfcz1cqe5FBiciw6AF4vgZaxY6AfVTbpTNp08jMUgexy","date":"Apr 2022","amount":"$8M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Rimonci Capital","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/rimonci-capital-1","logokey":"$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","tagline":"","urlname":"/investor_page/rimonci-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCRwd68CAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"LdAZP2zGpyvOdoL6lLHzp4Nnt0GyIYyKG8xFzAZKK9Gqrm7PJfBcKB","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","leadcaption":"","followupcaption":"Follow on "},{"name":"Yongzhu","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/yongzhu","logokey":null,"tagline":"-","urlname":"/investor_page/yongzhu","isisraeli":null,"investorid":"74x87iWDAUtXhMZuVkce5nF0B01qfie6LktZQx0AqpJVw9M4JAOLLf","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"arGSzXdjYrA1mp4Fa17XPlHMyiMedFOlrnbgwpdC8lwtBUwAoOShP7","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Zhuhai Ruikun","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/zhuhai-ruikun","logokey":null,"tagline":"-","urlname":"/investor_page/zhuhai-ruikun","isisraeli":null,"investorid":"btCrZyOaor76fiPgGjEcKplt6DQHGi2WOLmeOGCY3ibeI9hQ2ezuc5","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"nTAR0xHxiEoYpJXfnDysouXChuklv3rGzCJjFDnh5SW5LLJN7j2mIc","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Santen Ventures","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/santen-ventures","logokey":"$my2H9Qiy45bzYHZEhpi2NPTRGNPbN0bbhtNvDNhK3NyRPave2lec8j","tagline":"","urlname":"/investor_page/santen-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCxhMaTCAw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"wVQtKsPKPlS8CAWfrKYxKHGSdLexXJSKOZD3tAMDWCXhZSqbiXkr46","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$my2H9Qiy45bzYHZEhpi2NPTRGNPbN0bbhtNvDNhK3NyRPave2lec8j","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODR1K2eCgw","date":"Jul 2020","amount":"$16M","source":"https://en.globes.co.il/en/article-israeli-ai-eye-tracking-co-novasight-raises-8m-1001335659","eventtype":"FundingRoundEvent","investment":[{"name":"Rimonci Capital","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/rimonci-capital-1","logokey":"$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","tagline":"","urlname":"/investor_page/rimonci-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCRwd68CAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"720cde32-ef20-4b20-a25e-6fa1ceefb905","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","leadcaption":"Lead ","followupcaption":""},{"name":"Santen Ventures","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/santen-ventures","logokey":"$my2H9Qiy45bzYHZEhpi2NPTRGNPbN0bbhtNvDNhK3NyRPave2lec8j","tagline":"","urlname":"/investor_page/santen-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCxhMaTCAw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"6peJmRHhidULBPlnSOEa2laj0YuRPVn1xCIo0ufncbeJnleTWITYca","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$my2H9Qiy45bzYHZEhpi2NPTRGNPbN0bbhtNvDNhK3NyRPave2lec8j","leadcaption":"","followupcaption":""},{"name":"Club 100 Plus","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/club-100-plus","logokey":"$9KzK5hOWpM8gfEJtmPGC54W8YEkJIGaxbakzasODfvy01Mm8jNknA8.jpeg","tagline":"","urlname":"/investor_page/club-100-plus","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODk7rvICww","fundingtype":"Angel Group","leadpartner":null,"investmentid":"ec7tcMXJnKrBN2vJk8cbFj7SD7l6y49gLHqfrtQ7C62xEViXQf69As","fundingsubtype":"Angel Group","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9KzK5hOWpM8gfEJtmPGC54W8YEkJIGaxbakzasODfvy01Mm8jNknA8.jpeg","leadcaption":"","followupcaption":""},{"name":"Essilor","type":"Company","amount":null,"hidden":true,"country":"France","fullurl":"/company_page/essilor","logokey":"$7ZVYgyhiaY5YqNOfo7W1oC5iDCO8lYhbeXe7jQBWymDsiV60Q2Ro4Z","tagline":"","urlname":"/company_page/essilor","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkw6ulCww","fundingtype":"Company","leadpartner":null,"investmentid":"iIHwXs1ye5rg2lplEeDxmwDccXeWcRsZUi1g1xJ0gM6zCgr7atwWIz","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7ZVYgyhiaY5YqNOfo7W1oC5iDCO8lYhbeXe7jQBWymDsiV60Q2Ro4Z","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":16000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"B0ljLvygtJ5beLoTtFPUDHw8nRHCypYpeH00mAk859Z3OWZU8DavEg","date":"Jan 2019","amount":"$1.13M","source":"https://nova-sight.com/partners-page/","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1130000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODl28TACAw","date":"Jan 2015","amount":"$840K","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"jUx4LzENHgX290aPdO7BzfvDvc4BzhO1BVFFDVen16fBXK50zlAD51","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":840000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"2/2016","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"NovaSight","logourl":"https://storage.googleapis.com/clean-finder-353810/$xmyFeivd3V6f8mvAA8VWJ3ceJHjcgbG1u99SqtWjtpwRNvXVbRJcMc","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$xmyFeivd3V6f8mvAA8VWJ3ceJHjcgbG1u99SqtWjtpwRNvXVbRJcMc","seoabout":"NovaSight is medical device company with a mission to prevent vision impairments among pediatric patients using eye tracking based technology in novel diag...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":6,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Digital Medical Diagnostics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Semiconductors & Electronics","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA","classificationName":"coretechnology"},{"depth":2,"name":"Wearables","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pv12fQLDA","classificationName":"coretechnology"},{"depth":1,"name":"Platforms & Interfaces","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","classificationName":"coretechnology"},{"depth":2,"name":"Software","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","classificationName":"coretechnology"},{"depth":1,"name":"Data Storage","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","classificationName":"coretechnology"},{"depth":2,"name":"Cloud","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Deep Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","classificationName":"coretechnology"},{"depth":2,"name":"Computer Vision","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Children","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8u-QLDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","TechnologyClassificationModel>Semiconductors & Electronics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA>Wearables#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pv12fQLDA","TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA>Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","TechnologyClassificationModel>Semiconductors & Electronics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA","TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","TechnologyClassificationModel>Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA>Cloud#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Deep Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","TechnologyClassificationModel>Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Computer Vision#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA>Digital Medical Diagnostics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA>Children#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8u-QLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA/Digital Medical Diagnostics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Semiconductors & Electronics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA|2:>TechnologyClassificationModel>Semiconductors & Electronics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA/Wearables#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pv12fQLDA|1:>TechnologyClassificationModel/Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA|2:>TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA/Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA|1:>TechnologyClassificationModel/Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA|2:>TechnologyClassificationModel>Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA/Cloud#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Deep Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Computer Vision#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA|2:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA/Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA|3:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA/Children#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8u-QLDA|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Medical Devices","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Treatment & Therapeutics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Treatment & Therapeutics"}]},{"title":"Digital Healthcare","key":"0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare","children":[{"title":"Digital Medical Diagnostics","key":"0-0-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare>Digital Medical Diagnostics"}]}]}],"targetCustomer":[{"title":"Consumers","key":"0-0","path":"IndustryClassificationModel>Consumers","children":[{"title":"Demographics & Family","key":"0-0-0","path":"IndustryClassificationModel>Consumers>Demographics & Family","children":[{"title":"Children","key":"0-0-0-0","path":"IndustryClassificationModel>Consumers>Demographics & Family>Children"}]}]},{"title":"Healthcare & Life Sciences","key":"0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-1-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Semiconductors & Electronics","key":"0-0","path":"TechnologyClassificationModel>Semiconductors & Electronics","children":[{"title":"Wearables","key":"0-0-0","path":"TechnologyClassificationModel>Semiconductors & Electronics>Wearables"}]},{"title":"Platforms & Interfaces","key":"0-1","path":"TechnologyClassificationModel>Platforms & Interfaces","children":[{"title":"Software","key":"0-1-0","path":"TechnologyClassificationModel>Platforms & Interfaces>Software"}]},{"title":"Data Storage","key":"0-2","path":"TechnologyClassificationModel>Data Storage","children":[{"title":"Cloud","key":"0-2-0","path":"TechnologyClassificationModel>Data Storage>Cloud"}]},{"title":"Artificial Intelligence","key":"0-3","path":"TechnologyClassificationModel>Artificial Intelligence","children":[{"title":"Deep Learning","key":"0-3-0","path":"TechnologyClassificationModel>Artificial Intelligence>Deep Learning"},{"title":"Computer Vision","key":"0-3-1","path":"TechnologyClassificationModel>Artificial Intelligence>Computer Vision"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Digital Medical Diagnostics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Semiconductors & Electronics","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA","classificationName":"coretechnology"},{"depth":2,"name":"Wearables","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pv12fQLDA","classificationName":"coretechnology"},{"depth":1,"name":"Platforms & Interfaces","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","classificationName":"coretechnology"},{"depth":2,"name":"Software","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","classificationName":"coretechnology"},{"depth":1,"name":"Data Storage","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","classificationName":"coretechnology"},{"depth":2,"name":"Cloud","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Deep Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","classificationName":"coretechnology"},{"depth":2,"name":"Computer Vision","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Children","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8u-QLDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Medical Devices","Medical Treatment & Therapeutics","Digital Healthcare","Digital Medical Diagnostics"],"coreTechnology":["Semiconductors & Electronics","Wearables","Platforms & Interfaces","Software","Data Storage","Cloud","Artificial Intelligence","Deep Learning","Computer Vision"],"targetCustomer":["Consumers","Demographics & Family","Children","Healthcare & Life Sciences","Healthcare","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"aBu2AwANuitKqwXAjOpwnbayn2Aby4ICBK1MoiQ8tM89eSnvNBS8Ua","date":"Jul 2025","amount":"Undisclosed","source":"Silent round - Eli Yered from Sanara Capital","eventtype":"FundingRoundEvent","investment":[{"name":"Sanara Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/sanara-capital","logokey":"$OtrwiBbgsSI76jjQf5e00ig2pAnDSClBhkfRBSLW92Zf7whDq9YrQr.jpeg","tagline":null,"urlname":"/investor_page/sanara-capital","isisraeli":1,"investorid":"5xOGxLkkR8sf5lZkhz50eFzCcebcLx4AdZMgruBnsbEkjIOO0mLnkG","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"xE02tp4C2uOvOvqwHHjGKQVmkXvEYzsa9liJYB5jYgUIh1ouVVXQa1","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$OtrwiBbgsSI76jjQf5e00ig2pAnDSClBhkfRBSLW92Zf7whDq9YrQr.jpeg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"bc7tbTIUaIKJHaAwT6WEqRBgPDfZJgx0vUePJZDj1R7uB9a6tNU0Kv","date":"Mar 2024","amount":"$5M","source":"https://www.calcalist.co.il/calcalistech/article/hyodfru1r?_atscid=7_134353_204082920_2559099_0_Txtetaxjxdshwhus8sp","eventtype":"FundingRoundEvent","investment":[{"name":"Infinity China","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/infinity-china","logokey":null,"tagline":"","urlname":"/investor_page/infinity-china","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCOzOinCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"cy7Mmti0Z25uAjOgbpg5iAfbvQGEfR6V9DI2YOz6DtrScm2TUjR9zF","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"JGhYTypY3TUfcz1cqe5FBiciw6AF4vgZaxY6AfVTbpTNp08jMUgexy","date":"Apr 2022","amount":"$8M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Rimonci Capital","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/rimonci-capital-1","logokey":"$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","tagline":"","urlname":"/investor_page/rimonci-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCRwd68CAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"LdAZP2zGpyvOdoL6lLHzp4Nnt0GyIYyKG8xFzAZKK9Gqrm7PJfBcKB","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","leadcaption":"","followupcaption":"Follow on "},{"name":"Yongzhu","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/yongzhu","logokey":null,"tagline":"-","urlname":"/investor_page/yongzhu","isisraeli":null,"investorid":"74x87iWDAUtXhMZuVkce5nF0B01qfie6LktZQx0AqpJVw9M4JAOLLf","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"arGSzXdjYrA1mp4Fa17XPlHMyiMedFOlrnbgwpdC8lwtBUwAoOShP7","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Zhuhai Ruikun","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/zhuhai-ruikun","logokey":null,"tagline":"-","urlname":"/investor_page/zhuhai-ruikun","isisraeli":null,"investorid":"btCrZyOaor76fiPgGjEcKplt6DQHGi2WOLmeOGCY3ibeI9hQ2ezuc5","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"nTAR0xHxiEoYpJXfnDysouXChuklv3rGzCJjFDnh5SW5LLJN7j2mIc","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Santen Ventures","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/santen-ventures","logokey":"$my2H9Qiy45bzYHZEhpi2NPTRGNPbN0bbhtNvDNhK3NyRPave2lec8j","tagline":"","urlname":"/investor_page/santen-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCxhMaTCAw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"wVQtKsPKPlS8CAWfrKYxKHGSdLexXJSKOZD3tAMDWCXhZSqbiXkr46","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$my2H9Qiy45bzYHZEhpi2NPTRGNPbN0bbhtNvDNhK3NyRPave2lec8j","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODR1K2eCgw","date":"Jul 2020","amount":"$16M","source":"https://en.globes.co.il/en/article-israeli-ai-eye-tracking-co-novasight-raises-8m-1001335659","eventtype":"FundingRoundEvent","investment":[{"name":"Rimonci Capital","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/rimonci-capital-1","logokey":"$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","tagline":"","urlname":"/investor_page/rimonci-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCRwd68CAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"720cde32-ef20-4b20-a25e-6fa1ceefb905","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","leadcaption":"Lead ","followupcaption":""},{"name":"Santen Ventures","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/santen-ventures","logokey":"$my2H9Qiy45bzYHZEhpi2NPTRGNPbN0bbhtNvDNhK3NyRPave2lec8j","tagline":"","urlname":"/investor_page/santen-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCxhMaTCAw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"6peJmRHhidULBPlnSOEa2laj0YuRPVn1xCIo0ufncbeJnleTWITYca","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$my2H9Qiy45bzYHZEhpi2NPTRGNPbN0bbhtNvDNhK3NyRPave2lec8j","leadcaption":"","followupcaption":""},{"name":"Club 100 Plus","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/club-100-plus","logokey":"$9KzK5hOWpM8gfEJtmPGC54W8YEkJIGaxbakzasODfvy01Mm8jNknA8.jpeg","tagline":"","urlname":"/investor_page/club-100-plus","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODk7rvICww","fundingtype":"Angel Group","leadpartner":null,"investmentid":"ec7tcMXJnKrBN2vJk8cbFj7SD7l6y49gLHqfrtQ7C62xEViXQf69As","fundingsubtype":"Angel Group","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9KzK5hOWpM8gfEJtmPGC54W8YEkJIGaxbakzasODfvy01Mm8jNknA8.jpeg","leadcaption":"","followupcaption":""},{"name":"Essilor","type":"Company","amount":null,"hidden":true,"country":"France","fullurl":"/company_page/essilor","logokey":"$7ZVYgyhiaY5YqNOfo7W1oC5iDCO8lYhbeXe7jQBWymDsiV60Q2Ro4Z","tagline":"","urlname":"/company_page/essilor","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkw6ulCww","fundingtype":"Company","leadpartner":null,"investmentid":"iIHwXs1ye5rg2lplEeDxmwDccXeWcRsZUi1g1xJ0gM6zCgr7atwWIz","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7ZVYgyhiaY5YqNOfo7W1oC5iDCO8lYhbeXe7jQBWymDsiV60Q2Ro4Z","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":16000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODl28TACAw","date":"Jan 2015","amount":"$840K","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"jUx4LzENHgX290aPdO7BzfvDvc4BzhO1BVFFDVen16fBXK50zlAD51","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":840000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"B0ljLvygtJ5beLoTtFPUDHw8nRHCypYpeH00mAk859Z3OWZU8DavEg","date":"Jan 2019","amount":"$1.13M","source":"https://nova-sight.com/partners-page/","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1130000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}